Current options for the management of postmenopausal osteoporosis

Bibliography

• Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445-8
   PubMed Web of Science ®Google Scholar
• Body JJ, Bergmann P, Boonen S, Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010;21:1657-80
   PubMed Web of Science ®Google Scholar
• Nevitt MC, Ettinger B, Black DM, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
   PubMed Web of Science ®Google Scholar
• Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-18
   PubMed Web of Science ®Google Scholar
• Lindsay R, Silverman SL, Cooper C, Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3
   PubMed Web of Science ®Google Scholar
• Center JR, Bliuc D, Nguyen TV, Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007;297:387-94
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, De Laet C, A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004;35:375-82
   PubMed Web of Science ®Google Scholar
• Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285-9
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Bruyere O, Cannata-Andia JB, Management of osteoporosis in the elderly. Curr Med Res Opin 2009;25:2373-87
   PubMed Web of Science ®Google Scholar
• Boonen S, Singer AJ. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture I. Curr Med Res Opin 2008;24:1781-8
   PubMed Web of Science ®Google Scholar
• Ioannidis G, Papaioannou A, Hopman WM, Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009;181:265-71
   PubMed Web of Science ®Google Scholar
• Cauley JA, Thompson DE, Ensrud KC, Risk of mortality following clinical fractures. Osteoporos Int 2000;11:556-61
   PubMed Web of Science ®Google Scholar
• Leibson CL, Tosteson AN, Gabriel SE, Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002;50:1644-50
   PubMed Web of Science ®Google Scholar
• Richmond J, Aharonoff GB, Zuckerman JD, Mortality risk after hip fracture. J Orthop Trauma 2003;17:53-6
   PubMed Web of Science ®Google Scholar
• Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr Soc 2004;52:685-90
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, van Staa T, Ariely R, Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009;20:1633-50
   PubMed Web of Science ®Google Scholar
• Salkeld G, Cameron ID, Cumming RG, Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000;320:341-6
   PubMed Web of Science ®Google Scholar
• Rabenda V, Manette C, Lemmens R, The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int 2006;17:1346-52
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation. Osteoporosis in the European Community: a call to action. An audit of policy developments since 1998. IOF; 2001. Available from: http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/eu-report-2001.pdf [Last accessed 21 Sep 2011]
   Google Scholar
• Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38:S4-9
   Web of Science ®Google Scholar
• International Osteoporosis Foundation. Osteoporosis in the European union in 2008: ten years of progress and ongoing challenges. IOF; 2008. Available from: http://www.iofbonehealth.org/download/osteofound/filemanager/publications/pdf/eu-report-2008.pdf [Last accessed 12 Sep 2011]
   Google Scholar
• Kanis JA, Burlet N, Cooper C, European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008;19:399-428
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Wells G, Meta-analyses of therapies for postmenopausal osteoporosis. I. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:496-507
   PubMedGoogle Scholar
• Rizzoli R, Boonen S, Brandi ML, The role of calcium and vitamin D in the management of osteoporosis. Bone 2008;42:246-9
   PubMed Web of Science ®Google Scholar
• Boonen S, Bischoff-Ferrari HA, Cooper C, Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int 2006;78:257-70
   PubMed Web of Science ®Google Scholar
• Chapuy MC, Arlot ME, Duboeuf F, Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327:1637-42
   PubMed Web of Science ®Google Scholar
• Chapuy MC, Arlot ME, Delmas PD, Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 1994;308:1081-2
   PubMed Web of Science ®Google Scholar
• Chapuy MC, Pamphile R, Paris E, Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257-64
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Harris SS, Krall EA, Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670-6
   PubMed Web of Science ®Google Scholar
• Jackson RD, LaCroix AZ, Gass M, Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83
   PubMed Web of Science ®Google Scholar
• Lips P, Graafmans WC, Ooms ME, Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med 1996;124:400-6
   PubMed Web of Science ®Google Scholar
• Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469-72
   PubMed Web of Science ®Google Scholar
• Heikinheimo RJ, Inkovaara JA, Harju EJ, Annual injection of vitamin D and fractures of aged bones. Calcif Tissue Int 1992;51:105-10
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005;293:2257-64
   PubMed Web of Science ®Google Scholar
• Boonen S, Lips P, Bouillon R, Need for additional calcium to reduce the risk of hip fracture with vitamin D supplementation: evidence from a comparative metaanalysis of randomized controlled trials. J Clin Endocrinol Metab 2007;92:1415-23
   PubMed Web of Science ®Google Scholar
• Bischoff-Ferrari HA, Willett WC, Wong JB, Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009;169:551-61
   PubMed Web of Science ®Google Scholar
• Tang BM, Eslick GD, Nowson C, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet 2007;370:657-66
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006;21:1565-70
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Grey A, Avenell A, Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011;342:d2040
   PubMed Web of Science ®Google Scholar
• Lewis JR, Calver J, Zhu K, Calcium supplementation and the risks of atherosclerotic vascular disease in older women: results of a 5-year RCT and a 4.5-year follow-up. J Bone Miner Res 2011;26:35-41
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Seeman E, Crans GG, Diez-Perez A, Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. Osteoporos Int 2006;17:313-16
   PubMed Web of Science ®Google Scholar
• Martino S, Cauley JA, Barrett-Connor E, Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004;96:1751-61
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
   PubMed Web of Science ®Google Scholar
• Neele SJ, Evertz R, De Valk-De Roo G, Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Vogel VG, Costantino JP, Wickerham DL, Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010;47:729-35
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049-54
   PubMed Web of Science ®Google Scholar
• Silverman SL, Chines AA, Kendler DL, Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int Jul 2011. [Epub ahead of print]
   Google Scholar
• Genant HK. Bazedoxifene: a new selective estrogen receptor modulator for postmenopausal osteoporosis. Menopause Int 2011;17:44-9
   PubMedGoogle Scholar
• Liberman UA, Weiss SR, Broll J, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-82
   PubMed Web of Science ®Google Scholar
• Karpf DB, Shapiro DR, Seeman E, Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. JAMA 1997;277:1159-64
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002;23:508-16
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-99
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cummings SR, Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res 2010;25:976-82
   PubMed Web of Science ®Google Scholar
• de Groen PC, Lubbe DF, Hirsch LJ, Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 2000;12:1-12
   PubMedGoogle Scholar
• Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 2009;25:449-52
   PubMed Web of Science ®Google Scholar
• Perkins AC, Blackshaw PE, Hay PD, Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects. Clin Ther 2008;30:834-44
   PubMed Web of Science ®Google Scholar
• Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009;30:213-21
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91
   PubMed Web of Science ®Google Scholar
• Watts NB, Josse RG, Hamdy RC, Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003;88:542-9
   PubMed Web of Science ®Google Scholar
• Harrington JT, Ste-Marie LG, Brandi ML, Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;74:129-35
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
   PubMed Web of Science ®Google Scholar
• Boonen S, McClung MR, Eastell R, Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004;52:1832-9
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Cranney A, Tugwell P, Adachi J, Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 2002;23:517-23
   PubMed Web of Science ®Google Scholar
• Brown JP, Kendler DL, McClung MR, The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002;71:103-11
   PubMed Web of Science ®Google Scholar
• Delmas PD, Benhamou CL, Man Z, Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 2008;19:1039-45
   PubMed Web of Science ®Google Scholar
• Chesnut IC, Skag A, Christiansen C, Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
   PubMed Web of Science ®Google Scholar
• Reginster JY, Adami S, Lakatos P, Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 2006;65:654-61
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Lakatos P, Lorenc R, Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Clin Rheumatol 2008;27:955-60
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells GA, Yetisir E, Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-7
   PubMed Web of Science ®Google Scholar
• Harris ST, Blumentals WA, Miller PD. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 2008;24:237-45
   PubMed Web of Science ®Google Scholar
• Sebba AI, Emkey RD, Kohles JD, Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 2009;44:423-7
   PubMedGoogle Scholar
• Miller PD, Epstein S, Sedarati F, Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Curr Med Res Opin 2008;24:207-13
   PubMed Web of Science ®Google Scholar
• von Moos R, Caspar CB, Thurlimann B, Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. Ann Oncol 2008;19:1266-70
   PubMed Web of Science ®Google Scholar
• Body JJ, Diel IJ, Lichinitser MR, Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003;14:1399-405
   PubMed Web of Science ®Google Scholar
• Boonen S, Haentjens P, Vandenput L, Preventing osteoporotic fractures with antiresorptive therapy: implications of microarchitectural changes. J Intern Med 2004;255:1-12
   PubMed Web of Science ®Google Scholar
• Watts NB, Cooper C, Lindsay R, Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 2004;7:255-61
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
   PubMed Web of Science ®Google Scholar
• Recker RR, Delmas PD, Halse J, Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008;23:6-16
   PubMed Web of Science ®Google Scholar
• Lyles KW, Colon-Emeric CS, Magaziner JS, Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
   PubMed Web of Science ®Google Scholar
• Colon-Emeric CS, Mesenbrink P, Lyles KW, Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010;25:91-7
   PubMed Web of Science ®Google Scholar
• Recker RR, Lewiecki EM, Miller PD, Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009;122:S22-32
   PubMed Web of Science ®Google Scholar
• Boonen S, Vanderschueren D, Venken K, Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. J Intern Med 2008;264:315-32
   PubMed Web of Science ®Google Scholar
• Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis. Drug Saf 2009;32:219-28
   PubMed Web of Science ®Google Scholar
• Boonen S, Sellmeyer DE, Lippuner K, Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008;74:641-8
   PubMed Web of Science ®Google Scholar
• Khan AA, Sandor GK, Dore E, Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36:478-90
   PubMed Web of Science ®Google Scholar
• Lo JC, O'Ryan FS, Gordon NP, Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-53
   PubMed Web of Science ®Google Scholar
• Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67:61-70
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Burlet N, Cahall D, Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008;42:841-7
   PubMed Web of Science ®Google Scholar
• devogealer JP, Reginster J, Rompen E, L'osteonecrose maxillaire associee aux traitements aux bisphosphonates dans le traitement de l'osteoporose. Consensus interdisciplinaire. Louvain Med 2010;8:305-9
   Google Scholar
• Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6
   PubMed Web of Science ®Google Scholar
• Schneider JP. Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk. Geriatrics 2009;64:18-23
   PubMed Web of Science ®Google Scholar
• Neviaser AS, Lane JM, Lenart BA, Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008;22:346-50
   PubMed Web of Science ®Google Scholar
• Kwek EB, Goh SK, Koh JS, An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224-31
   PubMed Web of Science ®Google Scholar
• Rizzoli R, Akesson K, Bouxsein M, Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011;22:373-90
   PubMed Web of Science ®Google Scholar
• Chapurlat RD, Arlot M, Burt-Pichat B, Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007;22:1502-9
   PubMed Web of Science ®Google Scholar
• Stepan JJ, Burr DB, Pavo I, Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007;41:378-85
   PubMed Web of Science ®Google Scholar
• Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095-102
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011;364:1728-37
   PubMed Web of Science ®Google Scholar
• Weycker D, Macarios D, Edelsberg J, Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006;17:1645-52
   PubMed Web of Science ®Google Scholar
• Rabenda V, Vanoverloop J, Fabri V, Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Joint Surg Am 2008;90:2142-8
   PubMed Web of Science ®Google Scholar
• Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006;12:522-8
   PubMedGoogle Scholar
• Dempster DW, Cosman F, Parisien M, Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Chen P, Satterwhite JH, Licata AA, Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20:962-70
   PubMed Web of Science ®Google Scholar
• Dobnig H, Sipos A, Jiang Y, Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 2005;90:3970-7
   PubMed Web of Science ®Google Scholar
• Eastell R, Krege JH, Chen P, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 2006;22:61-6
   PubMed Web of Science ®Google Scholar
• Marcus R, Wang O, Satterwhite J, The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23
   PubMed Web of Science ®Google Scholar
• Dawson-Hughes B, Chen P, Krege JH. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab 2007;92:4630-6
   PubMedGoogle Scholar
• Neer RM, Arnaud CD, Zanchetta JR, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Lindsay R, Scheele WH, Neer R, Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Deal C, Omizo M, Schwartz EN, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 2005;20:1905-11
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357:905-16
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
   PubMed Web of Science ®Google Scholar
• Miller PD, Bilezikian JP, Diaz-Curiel M, Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide. J Clin Endocrinol Metab 2007;92:3535-41
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Hanley DA, Ettinger MP, Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003;88:5212-20
   PubMed Web of Science ®Google Scholar
• Greenspan SL, Bone HG, Ettinger MP, Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007;146:326-39
   PubMed Web of Science ®Google Scholar
• Reginster JY, Malaise O, Neuprez A, Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 2007;61:324-8
   PubMedGoogle Scholar
• Meunier PJ, Roux C, Seeman E, The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Canalis E, Hott M, Deloffre P, The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517-23
   PubMed Web of Science ®Google Scholar
• Baron R, Tsouderos Y. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation. Eur J Pharmacol 2002;450:11-17
   PubMedGoogle Scholar
• Takahashi N, Sasaki T, Tsouderos Y, S 12911-2 inhibits osteoclastic bone resorption in vitro. J Bone Miner Res 2003;18:1082-7
   PubMed Web of Science ®Google Scholar
• Hurtel-Lemaire AS, Mentaverri R, Caudrillier A, The calcium-sensing receptor is involved in strontium ranelate-induced osteoclast apoptosis. New insights into the associated signaling pathways. J Biol Chem 2009;284:575-84
   PubMed Web of Science ®Google Scholar
• Bonnelye E, Chabadel A, Saltel F, Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 2008;42:129-38
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Spector T, Badurski J. A short-term run-in study can significantly contribute to increasing the quality of long-term osteoporosis trials. The strontium ranelate phase III program. Osteoporos Int 2002;13:S30
   Google Scholar
• Reginster JY, Felsenberg D, Boonen S, Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX((R)). Osteoporos Int 2011;22:2347-55
   PubMed Web of Science ®Google Scholar
• Reginster JY, Sawicki A. Roces-Varela. Strontium ranelate: 8 years efficacy on vertebral and nonvertebral fractures in post menopausal osteoporotic women. Osteoporos Int 2008;19:S131-2
   Google Scholar
• Seeman E, Vellas B, Benhamou C, Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006;21:1113-20
   PubMed Web of Science ®Google Scholar
• Rolland Y, Abellan Van Kan G, Gillette-Guyonnet S, Strontium ranelate and risk of vertebral fractures in frail osteoporotic women. Bone 2011;48:332-8
   PubMedGoogle Scholar
• Seeman E, Devogelaer JP, Lorenc R, Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 2008;23:433-8
   PubMedGoogle Scholar
• Bruyere O, Roux C, Detilleux J, Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007;92:3076-81
   PubMed Web of Science ®Google Scholar
• Shea B, Wells G, Cranney A, Calcium supplementation on bone loss in postmenopausal women. Cochrane Database Syst Rev 2004;CD004526
   Google Scholar
• European Medicines Agency. Question and answers on the safety of Protelos/Osseor (strontium ranelate). EMEA; 2007. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/protelos/Protelos_Q&A_53461307en.pdf [Last accessed 12 Sep 2011]
   Google Scholar
• Grosso A, Douglas I, Hingorani A, Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008;66:689-94
   PubMed Web of Science ®Google Scholar
• Musette P, Brandi ML, Cacoub P, Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010;21:723-32
   PubMed Web of Science ®Google Scholar
• Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatology 2003;206:353-6
   PubMed Web of Science ®Google Scholar
• Sainz M, del Pozo JG, Arias LH, Strontium ranelate may cause alopecia. BMJ 2009;338:b1494
   Google Scholar
• McClung MR, Lewiecki EM, Cohen SB, Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821-31
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Miller PD, McClung MR, Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-41
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• von Keyserlingk C, Hopkins R, Anastasilakis A, Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis. Semin Arthritis Rheum 24 May 2011. [Epub ahead of print]
   PubMedGoogle Scholar
• Brown JP, Prince RL, Deal C, Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009;24:153-61
   PubMed Web of Science ®Google Scholar